The companies have started a collaboration worth up to $3.4 billion to develop a portfolio of degrader-antibody conjugates, a potentially new class of antibodies that selectively kill cancer cells.
Alnylam Pharmaceuticals is already making progress on its July 2023 deal with Roche to co-develop and commercialize zilebesiran, the former’s investigational RNAi therapeutic. The Cambridge biotech reported positive topline Phase II results Thursday for its partnered gene-silencing therapy to treat hypertension.
The trial data reinforces the potential for zilebesiran to offer “new possibilities in a field of medicine that has seen limited innovation in nearly 20 years,” said Simon Fox, program lead for the drug’s development.
The new multidisciplinary offering addresses industry need for more inclusive clinical trials and product development.
Biotech Beam Therapeutics has dosed the first patient in a Phase I/II study of its base-edited CAR-T therapy in relapsed or refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.
XtalPi, a global leader in AI-powered drug discovery, and Parthenon Therapeutics, a clinical-stage biotechnology company dedicated to reprogramming the tumor microenvironment, announced their collaboration today to discover novel therapeutic antibodies for the treatment of solid tumors.
Tonix Pharmaceuticals Holding Corp. said on Tuesday its experimental drug failed to meet the primary goal in a mid-stage study for management of widespread muscle pain and tenderness associated with long COVID-19.
Interim data from the Phase III innovaTV 301 trial showed that Genmab and Seagen’s antibody-drug conjugate Tivdak (tisotumab vedotin-tftv) met its primary endpoint, leading to significant survival benefit in patients with metastatic cervical cancer, the companies announced Monday.
BioNTech’s licensed antibody-drug conjugate is moving on to Phase III testing in a potential effort to challenge AstraZeneca and Daiichi Sankyo’s blockbuster Enhertu in a heavily treated breast cancer subpopulation. DualityBio, BioNTech’s partner and the ADC’s creator, posted the trial plans Wednesday.
While a majority of adults recognize leukemia as a blood cancer, a new survey by The Leukemia & Lymphoma Society (LLS) found that a low percentage of respondents associate the following diseases with a blood cancer: lymphoma (including Hodgkin’s lymphoma), myeloma, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs).